Adding TACE to Lenvatinib Boosts Survival in Advanced Liver Cancer

(MedPage Today) -- Combining transarterial chemoembolization (TACE) with lenvatinib (Lenvima) as first-line treatment for advanced hepatocellular carcinoma (HCC) prolonged survival compared with lenvatinib alone, the phase III LAUNCH trial showed...